Consultation on Canadian HIV Vaccine Initiative (CHVI) Funding Programs
(February 10-12, 2008) - Summary
On February 10-12, 2008, CHVI participating departments and agencies (Canadian International Development Agency, Public Health Agency of Canada, Industry Canada, Canadian Institutes of Health Research, and Health Canada), hosted a consultation on funding programs in Ottawa.
The objective of the Consultation was primarily to seek input on three new CHVI funding programs focussing on discovery and social research; clinical trials capacity building and networks; and policy development and community engagement. As well, the consultation provided opportunities for cross-sectoral networking and information-sharing on the CHVI.
A broad spectrum of domestic and international stakeholders attended the meeting, including representatives from Canadian and international research institutions, non-governmental organizations, the private sector, provincial and territorial governments, participating departments/agencies and other federal departments.
Participant List
A key component of the meeting comprised presentations on
This was followed by intensive discussions where participants contributed expert advice on priorities and areas of focus.
The results of discussions at the Consultation will be used to inform the development of the Request for Proposals/Application. A final report of the meeting will be published in the weeks ahead . In addition, ongoing committees; information-sharing fora and other mechanisms for the CHVI will be established.
The first of the CHVI discovery and social research (DSR) funding opportunities, the Operating Grants were launched in June 2008 by CIHR. The second of the DSR funding opportunities, the Catalyst Grants
, launched in August 2008 by CIHR, are intended as short-term seed money to support Canadian researchers involved in innovative HIV vaccines-related research activities.
Community Initiatives Fund
Pilot Scale Manufacturing Capacity for HIV Vaccine Clinical Trial Lots
Policy and Regulatory Issues, Community and Social Dimensions
Pilot Scale HIV Vaccine Manufacturing Facility in Canada for Clinical Trial Lots
Deadline for Submissions: June10, 2008 at 4:00 PM EDT
Under the CHVI, the Government of Canada (specifically the Canadian International Development Agency, the Public Health Agency of Canada and Industry Canada) and the Bill & Melinda Gates Foundation have made it a priority to fund the establishment of a pilot scale manufacturing facility in Canada to increase the global capacity to produce HIV vaccine candidates for use in clinical trials.
This LOI Form is the first stage in the application process for funding for the Pilot Scale HIV Vaccine Manufacturing Facility in Canada for Clinical Trial Lot. Based on the strength of the LOI, selected applicants will be invited to complete and submit a full Application Form which will be due in late October 2008.
Prior to completing the LOI Form, please ensure you have reviewed the Invitation to Submit Applications (355 KB .pdf)
document which describes in detail the objectives of this project as well as the two stage process to apply document.
To be eligible for funding, Applicants must meet the following:
A university, post-secondary college or educational institution is considered eligible if it has its own board of directors.
The geographic location of the Applicant’s headquarters will not be restricted although the location of the facility must be in Canada. While the NPC is not required to be headquartered in Canada, it should have a presence in Canada.
For-profit organizations and not-for-profit organizations that are agencies of government will not be eligible for funding. However, it is expected that the Applicant will partner with for-profit and other organizations and/or individuals to access the necessary expertise and resources for this project.
An Applicant that is not certain whether it is eligible should contact the contact person named in the Notes to Applicants section for assistance in determining its eligibility. The contact person may request additional information to make a determination.
The maximum amount of funding available for this project is $88M.
All LOIs must be submitted in hardcopy by June 10, 2008 at 4:00PM EDT to the contact person identified below. Please refer to section “Notes to Applicants” of the LOI Form for additional requirements.
Any questions or requests for clarification regarding this funding opportunity must be submitted via email to secretariat@chvi-icvv.gc.ca. All questions and requests along with the associated responses will be posted anonymously on the CHVI Web site page within five (5) calendar days of receiving the question/request. Only questions and/or requests submitted up to seven days before the deadline for the LOI Form will be answered. Applicants are encouraged to check the Q&A Section of the CHVI Web site daily to keep up-to-date with any posted questions, answers and corrections.
Canadian HIV Vaccine Initiative Secretariat
c/o Office of HIV Vaccines
Public Health Agency of Canada
200 Eglantine Driveway
8th Floor, Jeanne Mance Building
AL 1908 B
Ottawa, Ontario Canada
K1A 0K9
Telephone: 613-952-5120
Facsmile: 613-946-7528
E-mail Address: secretariat@chvi-icvv.gc.ca